Clinical characteristics of enrolled patients with ITP
| Patient no. . | Sex/age (y) . | PLT (×109/L) . | Symptoms . | Anti-GP autoantibody . |
|---|---|---|---|---|
| 1 | Female/21 | 29 | PT + GH | (-) |
| 2 | Female/45 | 38 | GH + ME | GPIIb/IIIa(+) GPIb/IX(+) |
| 3 | Female/27 | 5 | ME | GPIIb/IIIa(+) GPIb/IX(+) |
| 4 | Female/34 | 1 | EC + GH | (-) |
| 5 | Female/60 | 11 | (-) | GPIIb/IIIa(+) GPIb/IX(+) |
| 6 | Female/19 | 32 | EP + GH | (-) |
| 7 | Male/33 | 6 | PT + GIH | (-) |
| 8 | Female/68 | 15 | PT + EC | GPIIb/IIIa(+) GPIb/IX(+) |
| 9 | Male/58 | 8 | EC + GH | (-) |
| 10 | Female/57 | 15 | PT + GH | (-) |
| 11 | Female/42 | 11 | (-) | GPIIb/IIIa(+) |
| 12 | Female/43 | 20 | PT + GH + CH | (-) |
| 13 | Male/55 | 33 | (-) | (-) |
| 14 | Female/57 | 15 | EC | GPIb/IX(+) |
| 15 | Male/23 | 35 | (-) | GPIb/IX(+) |
| 16 | Female/53 | 5 | EC | (-) |
| 17 | Male/52 | 13 | (-) | GPIb/IX(+) |
| 18 | Female/67 | 10 | PT+GH+ME | (-) |
| 19 | Male/64 | 13 | GH | GPIb/IX(+) |
| 20 | Male/58 | 35 | (-) | GPIb/IX(+) |
| 21 | Female/31 | 1 | PT+ME | (-) |
| 22 | Male/32 | 11 | PT | GPIIb/IIIa(+) |
| 23 | Male/40 | 19 | (-) | (-) |
| 24 | Female/31 | 24 | (-) | GPIIb/IIIa(+) |
| 25 | Female/71 | 21 | CH | GPIIb/IIIa(+) |
| Patient no. . | Sex/age (y) . | PLT (×109/L) . | Symptoms . | Anti-GP autoantibody . |
|---|---|---|---|---|
| 1 | Female/21 | 29 | PT + GH | (-) |
| 2 | Female/45 | 38 | GH + ME | GPIIb/IIIa(+) GPIb/IX(+) |
| 3 | Female/27 | 5 | ME | GPIIb/IIIa(+) GPIb/IX(+) |
| 4 | Female/34 | 1 | EC + GH | (-) |
| 5 | Female/60 | 11 | (-) | GPIIb/IIIa(+) GPIb/IX(+) |
| 6 | Female/19 | 32 | EP + GH | (-) |
| 7 | Male/33 | 6 | PT + GIH | (-) |
| 8 | Female/68 | 15 | PT + EC | GPIIb/IIIa(+) GPIb/IX(+) |
| 9 | Male/58 | 8 | EC + GH | (-) |
| 10 | Female/57 | 15 | PT + GH | (-) |
| 11 | Female/42 | 11 | (-) | GPIIb/IIIa(+) |
| 12 | Female/43 | 20 | PT + GH + CH | (-) |
| 13 | Male/55 | 33 | (-) | (-) |
| 14 | Female/57 | 15 | EC | GPIb/IX(+) |
| 15 | Male/23 | 35 | (-) | GPIb/IX(+) |
| 16 | Female/53 | 5 | EC | (-) |
| 17 | Male/52 | 13 | (-) | GPIb/IX(+) |
| 18 | Female/67 | 10 | PT+GH+ME | (-) |
| 19 | Male/64 | 13 | GH | GPIb/IX(+) |
| 20 | Male/58 | 35 | (-) | GPIb/IX(+) |
| 21 | Female/31 | 1 | PT+ME | (-) |
| 22 | Male/32 | 11 | PT | GPIIb/IIIa(+) |
| 23 | Male/40 | 19 | (-) | (-) |
| 24 | Female/31 | 24 | (-) | GPIIb/IIIa(+) |
| 25 | Female/71 | 21 | CH | GPIIb/IIIa(+) |
(-), no bleeding symptom; CH, cerebral hemorrhage; EC, ecchymoses; EP, epistaxis; GH, gingival hemorrhage; GIH, gastrointestinal hemorrhage; GP, glycoprotein; ME, menorrhagia; PT, petechiae.